Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Oct;181(19):3717-3742.
doi: 10.1111/bph.16438. Epub 2024 Jun 9.

Paraoxonase-2 agonist vutiglabridin promotes autophagy activation and mitochondrial function to alleviate non-alcoholic steatohepatitis

Gu-Choul Shin  1   2 , Hyeong Min Lee  3   4   5 , Nayeon Kim  1 , Jihyeon Hur  3 , Sang-Ku Yoo  5 , Yun Sun Park  5 , Hyung Soon Park  5 , Dongryeol Ryu  6 , Min-Ho Park  7 , Jung Hee Park  7   8 , Sang-Uk Seo  2 , Leo Sungwong Choi  5 , Martin Rønn Madsen  9 , Michael Feigh  9 , Kwang Pyo Kim  3   4 , Kyun-Hwan Kim  1
Affiliations

Paraoxonase-2 agonist vutiglabridin promotes autophagy activation and mitochondrial function to alleviate non-alcoholic steatohepatitis

Gu-Choul Shin et al. Br J Pharmacol. 2024 Oct.

Abstract

Background and purpose: Only limited therapeutic agents have been developed for non-alcoholic steatohepatitis (NASH). Glabridin, a promising anti-obesity candidate, has only limited druggability due to its low in vivo chemical stability and bioavailability. Therefore, we developed vutiglabridin (VUTI), which is based on a glabridin backbone, and investigated its mechanism of action in treating NASH in animal models.

Experimental approach: Anti-NASH effects of VUTI were determined in in vitro fatty liver models, spheroids of primary human hepatocytes and L02 normal liver cell lines. To identify VUTI possible cellular target/s, biotin-labelled VUTI was synthesized and underwent chemical proteomic analysis. Further, the evaluation of VUTI therapeutic efficacy was carried out using an amylin-NASH and high-fat (HF) diet-induced obese (DIO) mouse models. This was carried out using transcriptomic, lipidomic and proteomic analyses of the livers from the amylin-NASH mouse model.

Key results: VUTI treatment markedly reduces hepatic steatosis, fibrosis and inflammation by promoting lipid catabolism, activating autophagy and improving mitochondrial dysfunction, all of which are hallmarks of effective NASH treatment. The cellular target of VUTI was identified as paraoxonase 2 (PON2), a newly proposed protein target for the treatment of NASH, VUTI enhanced PON2 activity. The results using PON2 knockdown cells demonstrated that PON2 is important for VUTI- activation of autophagy, promoting mitochondrial function, decreasing oxidative stress and alleviating lipid accumulation under lipotoxic condition.

Conclusion and implications: Our data demonstrated that VUTI is a promising therapeutic for NASH. Targeting PON2 may be important for improving liver function in various immune-metabolic diseases including NASH.

Keywords: autophagy activation; non‐alcoholic fatty liver disease; paraoxonase‐2; vutiglabridin.

PubMed Disclaimer

References

REFERENCES

    1. Ahn, J., Lee, H., Jang, J., Kim, S., & Ha, T. (2013). Anti‐obesity effects of glabridin‐rich supercritical carbon dioxide extract of licorice in high‐fat‐fed obese mice. Food and Chemical Toxicology, 51, 439–445. https://doi.org/10.1016/j.fct.2012.08.048
    1. Alexander, S. P. H., Fabbro, D., Kelly, E., Mathie, A. A., Peters, J. A., Veale, E. L., Armstrong, J. F., Faccenda, E., Harding, S. D., Davies, J. A., Annett, S., Boison, D., Burns, K. E., Dessauer, C., Gertsch, J., Helsby, N. A., Izzo, A. A., Ostrom, R., Papapetropoulos, A., … Wong, S. S. (2023). The Concise Guide to PHARMACOLOGY 2023/24: Enzymes. British Journal of Pharmacology, 180, S289–S373. https://doi.org/10.1111/bph.16181
    1. Alexander, S. P. H., Kelly, E., Mathie, A. A., Peters, J. A., Veale, E. L., Armstrong, J. F., Buneman, O. P., Faccenda, E., Harding, S. D., Spedding, M., Cidlowski, J. A., Fabbro, D., Davenport, A. P., Striessnig, J., Davies, J. A., Ahlers‐Dannen, K. E., Alqinyah, M., Arumugam, T. V., Bodle, C., … Zolghadri, Y. (2023). The Concise Guide to PHARMACOLOGY 2023/24: Introduction and Other Protein Targets. British Journal of Pharmacology, 180, S1–S22. https://doi.org/10.1111/bph.16176
    1. Alexander, S. P. H., Roberts, R. E., Broughton, B. R. S., Sobey, C. G., George, C. H., Stanford, S. C., Cirino, G., Docherty, J. R., Giembycz, M. A., Hoyer, D., Insel, P. A., Izzo, A. A., Ji, Y., MacEwan, D. J., Mangum, J., Wonnacott, S., & Ahluwalia, A. (2018). Goals and practicalities of immunoblotting and immunohistochemistry: A guide for submission to the British Journal of Pharmacology. British Journal of Pharmacology, 175, 407–411. https://doi.org/10.1111/bph.14112
    1. Allard, J. P., Aghdassi, E., Mohammed, S., Raman, M., Avand, G., Arendt, B. M., Jalali, P., Kandasamy, T., Prayitno, N., Sherman, M., Guindi, M., Ma, D. W. L., & Heathcote, J. E. (2008). Nutritional assessment and hepatic fatty acid composition in non‐alcoholic fatty liver disease (NAFLD): A cross‐sectional study. Journal of Hepatology, 48, 300–307. https://doi.org/10.1016/j.jhep.2007.09.009